BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05228015 (IK-930 in Advanced Solid Tumors): BVCT ex-ante prediction vs. reported outcome

On 31 Oct 2023, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 28 May 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05228015
Drug Name
IK-930
Drug MoA
oral TEAD inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Advanced Solid Tumors
Human Patients
198
Sponsor
Ikena Oncology
Phase
Phase 1

Prediction of , index 1303

Prospective Prediction
Prediction Index
1303
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
FAILURE (statistically insignificant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
210 days in advance
Readout Data Interpretation
0% ORR.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Phase
Phase 1
Status
Terminated
Enrollment
67
Lead sponsor
Ikena Oncology
Conditions
Solid Tumors, Adult; Solid Tumor; Malignant Pleural Mesothelioma (MPM); Epithelioid Hemangioendothelioma (EHE); NF2 Deficient Mesothelioma; Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes; NF2 Deficiency; YAP1 or TAZ Gene Fusions
Interventions
DRUG: IK-930; DRUG: Osimertinib
Design
Non randomized · Sequential · None
Primary purpose
Treatment
Start
2022-01-07
Primary completion
2024-08-27
Completion
2024-09-09
Primary outcomes
  • Safety and tolerability of IK-930 (Through study completion, an average of 36 months)
  • Occurrence of Dose Limiting Toxicity during first treatment cycle (Approximately 1 year)
  • RP2D and/or MTD of IK-930 (Approximately 1 year)

NCT05228015 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials